Gufic Biosciences Limited (BOM:509079)

Market Cap	30.82B -12.6%
Revenue (ttm)	8.97B +10.8%
Net Income	500.38M -39.0%
EPS	4.99 -39.0%
Shares Out	100.28M
PE Ratio	61.62
Forward PE	n/a
Dividend	0.10 (0.03%)
Ex-Dividend Date	Sep 22, 2025

Volume	880
Average Volume	7,060
Open	308.70
Previous Close	307.30
Day's Range	300.00 - 308.70
52-Week Range	267.50 - 409.00
Beta	-0.08
RSI	56.61
Earnings Date	May 29, 2026

About Gufic Biosciences

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (P...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 1,484
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 509079

Financial Performance

In fiscal year 2025, Gufic Biosciences's revenue was 8.20 billion, an increase of 1.63% compared to the previous year's 8.07 billion. Earnings were 696.50 million, a decrease of -19.14%.